american diabetes association pancreatitis glp-1 receptor agonist history Risk of pancreatic cancer associated with therapy Favorable Effects of GLP-1 Receptor

protocol 2 evaluated subsequent adverse outcomes in those with pre-existing SUDs

Hamann CR, Chung C, Kaffenberger BH

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) mimic the endogenous GLP-1 hormone in its insulin-promoting and glucagon-inhibiting actions [1]

The use of GLP-1RAs in patients with obesity and HFpEF may have the following benefits: weight loss

We aim to revoke the association of pancreatic cancer with their use in support of their continued use due to their beneficial cardiovascular and renal effects

After lunch, nutrition whiz Christine Craig, MS, RDN, CDCES expertly details the latest in MNT and provides real strategies on translating this content to your clinical practice